Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
Companies Commented On
- Celgene Corp.
- MYOS Corp.
- StemCells Inc.
Dr. Robert J. Hariri is considered a visionary serial entrepreneur in biomedicine. The chairman and former CEO of Celgene Cellular Therapeutics, one of the world's largest human cellular therapeutics companies, Hariri has pioneered the use of stem cells and biomaterials to treat a range of life-threatening diseases. Dr. Hariri has more than 100 issued and pending patents, and has authored more than 100 published chapters, articles and abstracts. He is recognized for his discovery of pluripotent stem cells from the placenta, and is a member of the team that discovered tumor necrosis factor. Dr. Hariri was recipient of the Thomas Alva Edison Award in 2007 and 2011. He serves on numerous boards of directors, including MYOS Corp. and Provista Diagnostics Inc. He is a member of the board of visitors of the Columbia University School of Engineering and Applied Sciences and the Science and Technology Council of the College of Physicians and Surgeons, as well as a member of the scientific advisory board for the Archon XPRIZE for Genomics. Dr. Hariri is also a trustee of the J. Craig Venter Institute and the Liberty Science Center, and has been appointed commissioner of cancer research by New Jersey Governor Chris Christie. Dr. Hariri received his undergraduate training at Columbia College and Columbia University School of Engineering and Applied Sciences, and was awarded his M.D. and Ph.D. degrees from Cornell University Medical College. Dr. Hariri received his surgical training at the New York Hospital-Cornell Medical Center, and directed the Aitken Neurosurgery Laboratory and the Center for Trauma Research.
Harnessing the Power of Nature's Perfect Cells: Robert J. Hariri (5/22/14) Neurosurgeon and serial entrepreneur Robert J. Hariri, founder, chairman and chief science officer at Celgene Cellular Therapeutics, describes how his businesses address some of the great unmet needs in medicine in this interview with The Life Sciences Report. Hariri also discusses the special nature and advantages of placenta-derived stem cells, and an elegant solution to the scourge of muscle wasting in late-stage disease and advancing age that could apply to treatment of cardiovascular disease in the future.
"If all goes well, CUR's NSI-189 product will move into Phase 2 development in Q2/15, so that is a good advancement opportunity." (1/22/15) Neuralstem Inc. - The Life Sciences Report Interview with Edward Stopke More >
"ATHX completed enrollment in its Phase 2 stroke study before the new year, so the first 90-day results will emerge in Q1/15E." (1/22/15) Athersys Inc. - The Life Sciences Report Interview with Edward Stopke More >
"The research synergy with Gilead and Merck could prove fruitful for RNN in terms of acquisition potential." (1/22/15) Rexahn Pharmaceuticals Inc. - The Life Sciences Report Interview with Edward Stopke More >
"The vote of confidence CTH has received from The Michael J. Fox Foundation is very advantageous." (1/8/15) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Daniel Pearlstein More >
"The new year holds a great deal of promise for the field of regenerative medicine, with companies like NEO at the forefront." (12/30/14) NeoStem Inc. - The Life Sciences Report Interview with Steve Brozak More >